PHASE 1 Clinical Trial Complete

We are pleased to announce that MindBio’s scientific team has completed a world-first phase 1 clinical trial microdosing LSD to clinical trial participants who take the drug at home and out in the community in the same way they would take any other medication.

Excerpt from the Market Announcement:

Vancouver, British Columbia – May 3 rd , 2022 – Blackhawk Growth Corp. (CSE:BLR; Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to report that MindBio Therapeutics (“MindBio”) has completed its 12-month Phase 1 clinical trial microdosing LSD in 80 healthy participants. MindBio is developing a microdosing regimen using LSD to treat mental health disorders such as depression. To get these novel treatments to market, MindBio needs to prove safety and efficacy of the treatment using a rigorous clinical trial process. The Phase 1 Clinical Trial is the largest safety study of its kind that has ever been completed under a randomized, double blind placebo controlled discipline, the results of which will support development of MindBio’s intellectual property and progression towards commercialization of treatments for mental health conditions. MindBio is looking forward to analyzing the data from the Phase 1 clinical trial to further inform its planned Phase 2 clinical trials. MindBio is working towards creating a safe and effective microdosing regimen using psychedelics that can be prescribed by doctors to patients in the primary health care system.

Read the full Market Announcement here.